Crinetics Pharmaceuticals (CRNX) Equity Ratio (2017 - 2025)
Historic Equity Ratio for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to 0.9.
- Crinetics Pharmaceuticals' Equity Ratio rose 87.86% to 0.9 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.9, marking a year-over-year increase of 87.86%. This contributed to the annual value of 0.92 for FY2024, which is 883.4% up from last year.
- Per Crinetics Pharmaceuticals' latest filing, its Equity Ratio stood at 0.9 for Q3 2025, which was up 87.86% from 0.91 recorded in Q2 2025.
- In the past 5 years, Crinetics Pharmaceuticals' Equity Ratio registered a high of 0.95 during Q4 2021, and its lowest value of 0.85 during Q4 2023.
- In the last 5 years, Crinetics Pharmaceuticals' Equity Ratio had a median value of 0.91 in 2025 and averaged 0.9.
- Per our database at Business Quant, Crinetics Pharmaceuticals' Equity Ratio crashed by 647.72% in 2023 and then soared by 883.4% in 2024.
- Crinetics Pharmaceuticals' Equity Ratio (Quarter) stood at 0.95 in 2021, then dropped by 5.02% to 0.9 in 2022, then dropped by 5.53% to 0.85 in 2023, then increased by 8.83% to 0.92 in 2024, then dropped by 2.93% to 0.9 in 2025.
- Its Equity Ratio was 0.9 in Q3 2025, compared to 0.91 in Q2 2025 and 0.92 in Q1 2025.